| # | Title | Journal | Year | Citations |
|---|
| 1 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials | Lancet Oncology, The | 2015 | 1,369 |
| 2 | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study | Lancet Oncology, The | 2014 | 678 |
| 3 | Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases | European Respiratory Review | 2018 | 370 |
| 4 | Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study | Journal of Clinical Oncology | 2020 | 327 |
| 5 | A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis | Journal of Medical Genetics | 2008 | 214 |
| 6 | Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis | European Respiratory Journal | 2015 | 171 |
| 7 | Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON | Lancet Respiratory Medicine,the | 2019 | 160 |
| 8 | Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer | Clinical Cancer Research | 2020 | 142 |
| 9 | Distinct Characteristics of Pleuroparenchymal Fibroelastosis With Usual Interstitial Pneumonia Compared With Idiopathic Pulmonary Fibrosis | Chest | 2014 | 120 |
| 10 | Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study | Lung Cancer | 2016 | 118 |
| 11 | Impairment of Coronary Flow Reserve Evaluated by Phase Contrast Cine‐Magnetic Resonance Imaging in Patients With Heart Failure With Preserved Ejection Fraction | Journal of the American Heart Association | 2016 | 105 |
| 12 | Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality | European Radiology | 2012 | 103 |
| 13 | Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia | Histopathology | 2012 | 101 |
| 14 | Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset | Japanese Journal of Clinical Oncology | 2019 | 101 |
| 15 | Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment | Respiratory Research | 2011 | 100 |
| 16 | Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3 | Cancer Science | 2015 | 99 |
| 17 | Quality of Life with Gefitinib in Patients with EGFR ‐Mutated Non‐Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial | Oncologist | 2012 | 98 |
| 18 | Polymyxin B-immobilized Fiber Column (PMX) Treatment for Idiopathic Pulmonary Fibrosis with Acute Exacerbation: A Multicenter Retrospective Analysis | Internal Medicine | 2012 | 98 |
| 19 | A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study) | Respiratory Research | 2016 | 93 |
| 20 | Efficacy of inhaled N‐acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis | Respirology | 2012 | 92 |
| 21 | Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice | Respiratory Medicine | 2013 | 88 |
| 22 | Rapid Detection of Epidermal Growth Factor Receptor Mutations in Lung Cancer by the SMart-Amplification Process | Clinical Cancer Research | 2007 | 81 |
| 23 | Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases | Pathology International | 2012 | 81 |
| 24 | LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. | Journal of Clinical Oncology | 2012 | 74 |
| 25 | Japanese guideline for the treatment of idiopathic pulmonary fibrosis | Respiratory Investigation | 2018 | 72 |
| 26 | Prognostic Factors in Interstitial Lung Disease Associated with Primary Sjögren’s Syndrome: A Retrospective Analysis of 33 Pathologically–Proven Cases | PLoS ONE | 2013 | 69 |
| 27 | All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis | Respiratory Investigation | 2015 | 69 |
| 28 | Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia | Annals of Thoracic Surgery | 2015 | 66 |
| 29 | A nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan | Respiratory Investigation | 2013 | 65 |
| 30 | CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis | European Journal of Radiology | 2014 | 65 |
| 31 | Stress Perfusion Coronary Flow Reserve Versus Cardiac Magnetic Resonance for Known or Suspected CAD | Journal of the American College of Cardiology | 2017 | 64 |
| 32 | Risk factors for acute exacerbation of idiopathic pulmonary fibrosis – Extended analysis of pirfenidone trial in Japan | Respiratory Investigation | 2015 | 63 |
| 33 | Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial | Lung Cancer | 2019 | 62 |
| 34 | Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposal | Respiratory Investigation | 2019 | 62 |
| 35 | Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells | Atherosclerosis | 2010 | 61 |
| 36 | LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. | Journal of Clinical Oncology | 2012 | 60 |
| 37 | The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial | Respiratory Research | 2011 | 59 |
| 38 | Ultra-high-resolution computed tomography can demonstrate alveolar collapse in novel coronavirus (COVID-19) pneumonia | Japanese Journal of Radiology | 2020 | 57 |
| 39 | Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials | Clinical Lung Cancer | 2018 | 56 |
| 40 | Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion | European Respiratory Journal | 2019 | 56 |
| 41 | Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial | American Journal of Respiratory and Critical Care Medicine | 2020 | 56 |
| 42 | Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction | International Journal of Cardiology | 2015 | 53 |
| 43 | Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis | Internal Medicine | 2016 | 53 |
| 44 | Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial | Cancer Science | 2018 | 53 |
| 45 | Pleuroparenchymal fibroelastosis diagnosed by multidisciplinary discussions in Japan | Respiratory Medicine | 2018 | 53 |
| 46 | Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial | Infectious Diseases and Therapy | 2021 | 52 |
| 47 | Clinical features of usual interstitial pneumonia with anti‐neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis | Respirology | 2016 | 51 |
| 48 | HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma | Scientific Reports | 2017 | 50 |
| 49 | A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis | Journal of Thoracic Oncology | 2020 | 50 |
| 50 | Phase II study of nab‐paclitaxel + carboplatin for patients with non‐small‐cell lung cancer and interstitial lung disease | Cancer Science | 2019 | 49 |
